Disc Medicine (IRON) Common Equity (2020 - 2026)

Disc Medicine (IRON) has 7 years of Common Equity data on file, last reported at $688.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at $688.4 million, up 4.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $688.4 million (up 4.25% YoY), and the FY2025 annual result was $739.8 million, up 66.78% from the prior year.
• Common Equity slipped to $688.4 million in Q1 2026 per IRON's latest filing, from $739.8 million in the prior quarter.
• Over five years, Common Equity peaked at $739.8 million in Q4 2025 and troughed at -$98.5 million in Q3 2022.
• A 5-year average of $367.3 million and a median of $371.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 169.95% in 2022, then surged 548.44% in 2023.
• A 5-year view of Common Equity shows it stood at $176.6 million in 2022, then jumped by 95.43% to $345.1 million in 2023, then gained by 28.53% to $443.6 million in 2024, then surged by 66.78% to $739.8 million in 2025, then declined by 6.95% to $688.4 million in 2026.
• Business Quant data shows IRON's Common Equity at $688.4 million in Q1 2026, $739.8 million in Q4 2025, and $573.4 million in Q3 2025.